(MT Newswires) -- Lars Fruergaard Jorgensen, CEO of Novo Nordisk, has confirmed the $16.5 billion acquisition of Catalan to increase production capacity in response to growing demand for obesity and diabetes treatments. 
 
The company has already completed a new facility in North Carolina and is building two more in Denmark. The acquisition will accelerate the company's expansion, in addition to investments in Novo Nordisk's five existing sites. 
 
Novo Nordisk expects sustained demand for Ozempic and Wegovy, with a target population of more than 100 million Americans with a BMI greater than 30. The company expects demand to exceed supply for several years, despite a significant increase in production capacity.
 
The company is working on semaglutide pills to offer patients more options. Results of advanced studies on new treatments are expected before the end of the year. The company is considering how to introduce these pills for obesity, bearing in mind that they require more active ingredient than injections.

Bloomberg videos